Navigation Links
European Clot Management Device Market To Exceed $170 Million By 2022
Date:9/4/2013

TORONTO, Sept. 4, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European market for clot management devices will see moderate growth through 2022. Although a number of segments are mature, fast-growing segments such as endovascular treatments for acute ischemic stroke (AIS) and venous thromboembolism (VTE) will support overall revenue expansion.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

The neurovascular embolectomy device segment will undergo robust growth through 2022. Compared to the current standard of care, intravenous tissue plasminogen activator (IV t-PA), neuroembolectomy devices offer a longer therapeutic window after symptom onset. This is critical because AIS patients often reach the hospital beyond the time in which IV t-PA is effective. In addition, IV t-PA is ineffective for treating large clot burdens, whereas neurovascular embolectomy is fast and effective in the recanalization of large-vessel occlusions, offering an alternative treatment for these cases.

Similarly, although VTE is typically treated with anticoagulants, endovascular clot management treatment volumes for this indication will increase steadily as clinical data emerges to support the pharmacomechanical treatment of this condition, bolstering physician confidence. Additionally, there has been an increasing trend toward the combined use of percutaneous thrombectomy and catheter-directed thrombolysis (CDT), particularly for the treatment of acute cases of VTE.

"When used with CDT, thrombectomy may actually offer safety advantages compared to anticoagulants," said MRG Analyst Tony Su. "This treatment can reduce drug doses or eliminate the need for them altogether, resulting in fewer bleeding complications than with medical management. This advantage will increase adoption of percutaneous thrombectomy and CDT in the VTE indication, boosting procedure volumes and revenues."

Millennium Research Group's European Markets for Clot Management Devices 2013 reports include unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for percutaneous thrombectomy devices, embolectomy balloon catheters, CDT devices, inferior vena cava filters and neurovascular embolectomy devices in France, Germany, Italy, Spain and the United Kingdom. Supplemental country coverage is also available for Austria, Belgium, the Czech Republic, Denmark, Finland, Greece, Hungary, the Netherlands, Norway, Poland, Portugal, Romania, Sweden, Switzerland and Ukraine, as well as in aggregate for the rest of the European countries.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net

 


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
2. European Union Grants a Good Manufacturing Practice Certificate to Nelson Laboratories
3. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
4. European Urological Device Market Will Be Driven By Adoption Of New Minimally Invasive Devices
5. CryoLife Announces First European Implant Of HeRO Graft
6. The Emerging Eastern European Market For Interventional Cardiology Devices Will Grow To $282 Million By 2021
7. Mature US and European coronary artery bypass graft device markets will Shrink through 2021
8. US and European Computer Aided Detection (CAD) Industry
9. EAACI Publishes the First European Guidelines for food-Allergy Sufferers
10. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
11. European Orthopedic Market 2017 Forecasts: Hip, Knee & Shoulder Analysis in New Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):